AbCellera Biologics Inc. (NASDAQ: ABCL – Get a rating) major shareholder Holdings Ltd. Thermopylae purchased 64,545 shares of the company in a transaction dated Monday, June 6. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $484,087.50. Following the purchase, the insider now directly owns 55,580,303 shares of the company, valued at $416,852,272.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink. Major shareholders who own at least 10% of a company’s stock are required to disclose their sales and purchases to the SEC.
holdings ltd. Thermopylae has also recently made the following trade(s):
- On Thursday, May 12, Holdings Ltd. Thermopylae has purchased 1,408,468 shares of AbCellera Biologics. The shares were purchased at an average cost of $6.41 per share, for a total transaction of $9,028,279.88.
ABCL traded down $0.13 during Wednesday’s trading, hitting $7.96. The company’s shares had a trading volume of 1,439,757 shares, compared to its average volume of 1,958,264. The company’s 50-day moving average price is $8.17 and its moving average price over 200 days is $10.03. The stock has a market capitalization of $2.26 billion, a PE ratio of 12.23 and a beta of -0.28. AbCellera Biologics Inc. has a 12-month low of $5.42 and a 12-month high of $26.60.
AbCellera Biologics (NASDAQ: ABCL – Get a rating) last released its quarterly results on Tuesday, May 10. The company reported earnings per share of $0.54 for the quarter, beating the consensus estimate of $0.47 by $0.07. The company posted revenue of $316.58 million in the quarter, versus a consensus estimate of $208.96 million. AbCellera Biologics had a return on equity of 19.72% and a net margin of 41.87%. AbCellera Biologics revenue increased 56.2% year over year. During the same period a year earlier, the company posted EPS of $0.37. As a group, research analysts expect AbCellera Biologics Inc. to post EPS of 0.61 for the current year.
Several equity research analysts have recently commented on the company. Piper Sandler reduced her price target on AbCellera Biologics from $28.00 to $21.00 in a Wednesday, May 11 research note. BMO Capital Markets reaffirmed a “buy” rating and issued a target price of $40.00 on shares of AbCellera Biologics in a research note on Wednesday, May 11. SVB Leerink reduced its price target on AbCellera Biologics from $25.00 to $20.00 and set an “outperform” rating on the stock in a Friday, Feb. 25 research note. Zacks Investment Research downgraded AbCellera Biologics from a “buy” rating to a “hold” rating in a Wednesday, May 11 research note. Finally, Credit Suisse Group raised its price target on AbCellera Biologics from $39.00 to $40.00 and gave the company an “outperform” rating in a Friday, Feb. 25 research note. One equity research analyst gave the stock a hold rating and seven gave the stock a buy rating. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $26.08.
A number of institutional investors and hedge funds have recently changed their holdings in the company. Worth Asset Management LLC acquired a new stake in shares of AbCellera Biologics during Q1 valued at $25,000. Spire Wealth Management acquired a new equity stake in AbCellera Biologics during Q4 valued at $29,000. Evoke Wealth LLC increased its equity stake in AbCellera Biologics by 280.3% during Q3. Evoke Wealth LLC now owns 2,985 shares of the company worth $59,000 after purchasing an additional 2,200 shares in the last quarter. Bank of America Corp DE increased its equity stake in AbCellera Biologics by 67.9% during the 4th quarter. Bank of America Corp DE now owns 4,108 shares of the company worth $59,000 after buying 1,661 additional shares in the last quarter. Finally, Eagle Bay Advisors LLC increased its equity stake in AbCellera Biologics by 44.0% during the 4th quarter. Eagle Bay Advisors LLC now owns 4,463 shares of the company worth $85,000 after purchasing 1,363 additional shares in the last quarter. Institutional investors hold 39.58% of the company’s shares.
About AbCellera Biologics (Get a rating)
AbCellera Biologics Inc is developing an antibody discovery platform. Its comprehensive artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs completed, in progress or under contract with 36 partners.
Get news and reviews for AbCellera Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for AbCellera Biologics and related companies with MarketBeat.com’s FREE daily newsletter.